Arizona is currently home to 1787 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
NCT04232566
Recruiting
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
03/23/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
Register for Updates
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
NCT05676255
Recruiting
Many breast cancer survivors (estimated 70% in some studies) experience clinically significant depression and/or anxiety in the months and years after finishing cancer treatments. This research will build on the rigor of prior research to reduce breast cancer survivor depression and anxiety with a compassion meditation intervention called CBCT (Cognitively-Based Compassion Training) for online synchronous delivery that is also inclusive of informal caregivers (i.e., adult family members who live... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2023
Locations: University of Arizona, Tucson, Arizona
Conditions: Breast Cancer Female, Psychological Distress
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Langerhans Cell Histiocytosis
Register for Updates
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Breast Cancer
Register for Updates
Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®
NCT05333211
Recruiting
Phase I/II, multi-center, prospective, blinded 2arm, parallel design and randomized controlled study. Assessing the Ortho-R/PRP combination and standard of care for rotator cuff repair, will be compared though 12 months.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
03/17/2023
Locations: Tucson Orthopedics, Tucson, Arizona
Conditions: Rotator Cuff Tears
Register for Updates
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
NCT04079179
Recruiting
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.
Gender:
All
Ages:
All
Trial Updated:
03/13/2023
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
Register for Updates
A Study of ICP-192 in Patients With Advanced Solid Tumors
NCT04565275
Recruiting
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2023
Locations: Arizona Oncology, Tucson, Arizona
Conditions: Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
Register for Updates
Hydroxyurea Optimization Through Precision Study
NCT03789591
Recruiting
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will be recruited from the pediatric sickle cell clin... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
03/09/2023
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
CardioFocus HeartLight Post-Approval Study
NCT03168659
Recruiting
This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2023
Locations: University of Arizona Sarver HeartCenter, Tucson, Arizona
Conditions: Atrial Fibrillation
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Tucson, Arizona
Conditions: Cystic Fibrosis
Register for Updates
Personal KinetiGraph® Clinical Validation Study
NCT05251701
Recruiting
The purpose of this study is to clinically validate new measures of the Personal KinetiGraph® (PKG®).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/02/2023
Locations: Tucson Neuroscience Research, Tucson, Arizona
Conditions: Movement Disorders, Parkinson Disease
Register for Updates
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02199665
Recruiting
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blockin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/02/2023
Locations: Mayo Clinic (AZ), Scottsdale, Arizona
Conditions: Refractory Multiple Myeloma
Register for Updates